Bioaffinity Technologies Warrant Stock Probability of Future Stock Price Finishing Over 50.39
| BIAFW Stock | USD 0.52 0.04 8.33% |
BioAffinity |
BioAffinity Technologies Target Price Odds to finish over 50.39
The tendency of BioAffinity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 50.39 or more in 90 days |
| 0.52 | 90 days | 50.39 | close to zero percent |
Based on a normal probability distribution, the odds of BioAffinity Technologies to move over $ 50.39 or more in 90 days from now is close to zero percent (This bioAffinity Technologies Warrant probability density function shows the probability of BioAffinity Stock to fall within a particular range of prices over 90 days) . Probability of BioAffinity Technologies price to stay between its current price of $ 0.52 and $ 50.39 at the end of the 90-day period is more than 93.0 .
Assuming the 90 days horizon bioAffinity Technologies Warrant has a beta of -0.88 suggesting Additionally BioAffinity Technologies Warrant has an alpha of 0.2198, implying that it can generate a 0.22 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). BioAffinity Technologies Price Density |
| Price |
Predictive Modules for BioAffinity Technologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as BioAffinity Technologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.BioAffinity Technologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. BioAffinity Technologies is not an exception. The market had few large corrections towards the BioAffinity Technologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold bioAffinity Technologies Warrant, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of BioAffinity Technologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.22 | |
β | Beta against Dow Jones | -0.88 | |
σ | Overall volatility | 0.33 | |
Ir | Information ratio | 0 |
BioAffinity Technologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of BioAffinity Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for BioAffinity Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| BioAffinity Technologies generated a negative expected return over the last 90 days | |
| BioAffinity Technologies has high historical volatility and very poor performance | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule |
BioAffinity Technologies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of BioAffinity Stock often depends not only on the future outlook of the current and potential BioAffinity Technologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. BioAffinity Technologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 8.7 M | |
| Cash And Short Term Investments | 2.8 M | |
| Shares Float | 8.6 M |
BioAffinity Technologies Technical Analysis
BioAffinity Technologies' future price can be derived by breaking down and analyzing its technical indicators over time. BioAffinity Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of bioAffinity Technologies Warrant. In general, you should focus on analyzing BioAffinity Stock price patterns and their correlations with different microeconomic environments and drivers.
BioAffinity Technologies Predictive Forecast Models
BioAffinity Technologies' time-series forecasting models is one of many BioAffinity Technologies' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary BioAffinity Technologies' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about BioAffinity Technologies
Checking the ongoing alerts about BioAffinity Technologies for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for BioAffinity Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| BioAffinity Technologies generated a negative expected return over the last 90 days | |
| BioAffinity Technologies has high historical volatility and very poor performance | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: Veterans Research Foundation Spotlights CyPath Lungs Addition to the Federal Supply Schedule |
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.